DFE Pharma, Sterling, and Harro Höfliger partner as “INTO” to offer DPI development services  

Inhaled lactose manufacturer DFE Pharma, API manufacturer Sterling, and filling/packaging company Harro Höfliger have partnered to create an early development service for DPIs called “INTO” (Inhalation Together). According to the INTO web site, the partnership will offer API development and characterization services, pre-formulation and formulation studies, and consulting services.

INTO says that it is “a combined service offering collective accountability increasing efficiency and effectiveness and making complex respiratory drug product development simpler, faster, economic, and easier to manage by offering a co-ordinated and aligned suite of services in one team, no gaps, everyone aligned and focused on meeting the clients’ targets, together.”

Sterling Chief Strategy Officer Russell Spencer commented, “We are pleased and excited to launch this novel alliance of skills and expertise providing combined and aligned service to those developing dry powder inhaler products. We believe this is an innovation in the field of complex CDMO support with a virtual model combining only as and when you need it avoiding cost and complexity while delivering a broad service offering.”

Read the INTO announcement.

Share

published on

Featured event:

October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden

October 21-October 22: MVIC Symposium, Lund, Sweden

October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany

November 10-November 11: Rescon Europe 2026, Porto, Portugal